| scholarly article | Q13442814 |
| P953 | full work available at URL | http://www.jbc.org/content/208/2/477 |
| P698 | PubMed publication ID | 13174557 |
| P50 | author | Gertrude B. Elion | Q35703 |
| George H. Hitchings | Q310487 | ||
| P2093 | author name string | G B ELION | |
| G H HITCHINGS | |||
| S SINGER | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 477-488 | |
| P577 | publication date | 1954-06-01 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites | |
| P478 | volume | 208 |
| Q28379406 | 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity |
| Q33836051 | 2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir |
| Q35627868 | A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments |
| Q83226114 | A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity |
| Q37512830 | A review of applications of metabolomics in cancer |
| Q34249277 | Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1. |
| Q35760812 | Activity of ceftizoxime combined with gentamicin against 100 clinical isolates of Pseudomonas aeruginosa |
| Q34974583 | Activity of sulfamethoxazole and trimethoprim against Bacteroides fragilis |
| Q28493107 | Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS |
| Q40621111 | Alafosfalin, a new inhibitor of cell wall biosynthesis: in vitro activity against urinary isolates in Japan and potentiation with beta-lactams |
| Q39478859 | Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling |
| Q35671354 | Antagonism of ampicillin and chloramphenicol for meningeal isolates of group B streptococci |
| Q37464515 | Antagonisms between purines and purine analogues in auxotrophs of Salmonella typhimurium |
| Q39832302 | Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone |
| Q39028198 | Anti-folates potentiate bactericidal effects of other antimicrobial agents |
| Q28378745 | Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase |
| Q35277955 | Anti-human immunodeficiency virus effects of dextran sulfate are strain dependent and synergistic or antagonistic when dextran sulfate is given in combination with dideoxynucleosides |
| Q28323830 | Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells |
| Q35717981 | Antibacterial activity and mechanism of action of phosphonopeptides based on aminomethylphosphonic acid |
| Q41034355 | Antibacterial activity of Co-trimazine in vitro and in vivo |
| Q39851746 | Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus |
| Q35671683 | Antibacterial properties of alafosfalin combined with cephalexin |
| Q36632795 | Antibiotic combinations: should they be tested? |
| Q28483846 | Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model |
| Q77727373 | Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics |
| Q35005445 | Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis |
| Q28361413 | Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A |
| Q37137408 | Assessment of the evolution of cancer treatment therapies |
| Q39856512 | Bactericidal activity of trimethoprim alone and in combination with sulfamethoxazole on susceptible and resistant Escherichia coli K-12. |
| Q42928358 | Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa |
| Q34916770 | Bacteriological Studies with Morphine-Like Narcotics: Relevance to Narcotic Actions in Mammals? |
| Q40281572 | Bacteriostatic and bactericidal activities of beta-lactam antibiotics enhanced by the addition of low concentrations of gentamicin |
| Q57497582 | Bioactive nano-metal-organic frameworks as antimicrobials against Gram-positive and Gram-negative bacteria |
| Q39849029 | Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin |
| Q34355578 | Calcium and calmodulin antagonists inhibit human malaria parasites (Plasmodium falciparum): implications for drug design |
| Q39471986 | Carbapenem derivatives as potential inhibitors of various beta-lactamases, including class B metallo-beta-lactamases. |
| Q40818384 | Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies |
| Q41785504 | Chloroquine susceptibility and reversibility in a Plasmodium falciparum genetic cross |
| Q92071692 | Clinically Approved Drugs Inhibit the Staphylococcus aureus Multidrug NorA Efflux Pump and Reduce Biofilm Formation |
| Q40232288 | Co-trimoxazole susceptibility tests improved with separate trimethoprim and sulfamethoxazole disks. |
| Q28366028 | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2 |
| Q35640110 | Comparative activities of selected combinations of acyclovir, vidarabine, arabinosyl hypoxanthine, interferon, and polyriboinosinic acid-polyribocytidylic acid complex against herpes simplex virus type 2 in tissue culture and intravaginally inoculat |
| Q39834313 | Comparative in vitro activity of coumermycin against methicillin-resistant Staphylococcus aureus |
| Q36755784 | Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime |
| Q40281323 | Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new). |
| Q72771816 | Comparative synergistic activity of netilmicin-piperacillin versus gentamicin-piperacillin |
| Q37206531 | Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotaxime and its metabolite against anaerobes |
| Q39834258 | Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains |
| Q37201989 | Cooperation of Doxycycline with Phytochemicals and Micronutrients Against Active and Persistent Forms of Borrelia sp |
| Q41132446 | Development of sulphonamide-trimethoprim combinations for urinary tract infections. Part I: Comparison of the antibacterial effect of sulphonamides alone and in combination with trimethoprim |
| Q40716375 | Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients |
| Q28344606 | Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens |
| Q39241916 | Effect of Ampicillin and Chloramphenicol Against Streptococcus pneumoniae and Neisseria meningitidis |
| Q34942375 | Effect of Surfactants on Antibiotic Resistance |
| Q36475674 | Effect of Two Cancer Chemotherapeutic Agents on the Antibacterial Activity of Three Antimicrobial Agents |
| Q35761276 | Effect of calcium, magnesium, and zinc on ticarcillin and tobramycin alone and in combination against Pseudomonas aeruginosa |
| Q33573365 | Effect of combinations of antiviral drugs on herpes simplex encephalitis. |
| Q35715001 | Effects of erythromycin in combination with penicillin, ampicillin, or gentamicin on the growth of Listeria monocytogenes |
| Q28378655 | Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1 |
| Q36468590 | Factors Influencing Susceptibility of Nocardia Species to Trimethoprim-Sulfamethoxazole |
| Q38726022 | Functional synergy between antimicrobial peptoids and peptides against Gram-negative bacteria |
| Q37643711 | Genetic basis for vancomycin-enhanced cephalosporin susceptibility in vancomycin-resistant enterococci revealed using counterselection with dominant-negative thymidylate synthase |
| Q34342264 | Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state |
| Q34276848 | Harmine is a potent antimalarial targeting Hsp90 and synergizes with chloroquine and artemisinin |
| Q36290493 | High-Throughput Intracellular Antimicrobial Susceptibility Testing of Legionella pneumophila |
| Q39834084 | In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum |
| Q41837012 | In vitro activity of antibiotics commonly used in the treatment of otitis media against Streptococcus pneumoniae isolates with different susceptibilities to penicillin |
| Q35713632 | In vitro activity of the two principal oxidative metabolites of metronidazole against Bacteroides fragilis and related species |
| Q44632608 | In vitro and in vivo synergy between ceftriaxone and aminoglycosides againstPseudomonas aeruginosa |
| Q42929722 | In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients |
| Q39834358 | In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones |
| Q42205383 | In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus |
| Q35116931 | In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans |
| Q67864973 | In vitro studies on drug interaction of ifosfamide and ACNU in primary and metastatic human brain tumours |
| Q40085711 | In vitro susceptibilities of ocular Bacillus cereus isolates to clindamycin, gentamicin, and vancomycin alone or in combination |
| Q35139159 | In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates |
| Q36753200 | In vitro synergy studies with Clostridium difficile |
| Q47137042 | Inhibition of Bacterial Growth by Peptide-Conjugated Morpholino Oligomers. |
| Q38991210 | Inhibition of Pseudomonas aeruginosa by Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers. |
| Q39869286 | Inhibition of vaccinia virus replication by two small interfering RNAs targeting B1R and G7L genes and their synergistic combination with cidofovir |
| Q39743397 | Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. |
| Q42115593 | Interactions of beta-lactam antibiotics and antineoplastic agents |
| Q36952188 | Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy |
| Q28369664 | L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor |
| Q40214688 | Low Trimethoprim Susceptibility of Anaerobic Bacteria Due to Insensitive Dihydrofolate Reductases |
| Q37618276 | M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures |
| Q44242557 | Mechanism of action of psoralens: isobologram analysis reveals that ultraviolet light potentiation of psoralen action is not additive but synergistic |
| Q36276904 | Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition |
| Q40314059 | Mechanisms of action of antibiotics. I. Additive action of chloramphenicol and tetracyclines on the growth of Escherichia coli. |
| Q35654790 | Microbial Kinetics and Dependencies of Individual and Combined Antibiotic Inhibitors of Protein Biosynthesis |
| Q40616737 | Microdilution transfer plate technique for determining in vitro synergy of antimicrobial agents |
| Q42377280 | Molecular mechanism of synergy between the antimicrobial peptides PGLa and magainin 2. |
| Q43719085 | Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients |
| Q34145455 | MurAA is required for intrinsic cephalosporin resistance of Enterococcus faecalis |
| Q34123691 | New Mycobacterium avium antifolate shows synergistic effect when used in combination with dihydropteroate synthase inhibitors |
| Q36480656 | Phosphonopeptides as antibacterial agents: alaphosphin and related phosphonopeptides |
| Q39856842 | Potent cephalosporinase inhibitors: 7 beta-[2-(1, 3-dithiolan-2-ylidene) acetamido] cephalosporins and related compounds |
| Q40281620 | Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis |
| Q37692343 | Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition |
| Q36432308 | Potentiation of the cytotoxic activity of copper by polyphosphate on biofilm-producing bacteria: a bioinspired approach |
| Q37311933 | Preclinical screening methods in cancer |
| Q28323976 | Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity |
| Q28361577 | Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro |
| Q28379459 | SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus |
| Q50590139 | Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells |
| Q47677580 | Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology |
| Q69892058 | Single-blind comparative trial of trimethoprim-sulphamethoxazole and ampicillin in the treatment of exacerbations of chronic bronchitis |
| Q72714996 | Studies on combined cytostatic therapy. The effect of cyclophosphamide and mitomycin C on the cortisone degradation of the liver |
| Q54263959 | Study of the Interactions Between Bacteriophage phiIPLA-RODI and Four Chemical Disinfectants for the Elimination of Staphylococcus aureus Contamination. |
| Q41132123 | Successful treatment of Batrachochytrium salamandrivorans infections in salamanders requires synergy between voriconazole, polymyxin E and temperature |
| Q35837943 | Sulphonamides and folic acid antagonists in malaria and toxoplasmosis. |
| Q40621462 | Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination |
| Q36473752 | Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing |
| Q24649755 | Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity |
| Q41790874 | Synergism between penicillin G and the antimicrobial ether lipid, rac-1-dodecylglycerol, acting below its critical micelle concentration |
| Q35131156 | Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model |
| Q40618456 | Synergism of fosfomycin-ampicillin and fosfomycin-chloramphenicol against Salmonella and Shigella |
| Q34985313 | Synergistic Activity of Trimethoprim and Amikacin Against Gram-Negative Bacilli |
| Q35640792 | Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa |
| Q39855408 | Synergistic activities of fortimicin A and beta-lactam antibiotics against Pseudomonas aeruginosa |
| Q35759902 | Synergistic antibacterial activity between L-norvalyl-L-1-aminoethylphosphonic acid and nocardicin A |
| Q35563027 | Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF |
| Q33752257 | Synergistic antiviral activities of oligonucleoside methylphosphonates complementary to herpes simplex virus type 1 immediate-early mRNAs 4, 5, and 1. |
| Q42115489 | Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro |
| Q27478091 | Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses |
| Q28330357 | Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro |
| Q39857155 | Synergistic interaction of trimethoprim and sulfamethoxazole on Paracoccidioides brasiliensis |
| Q50465428 | Synergy between verapamil and other multidrug -resistance modulators in model membranes |
| Q34384513 | Synergy of Nitric Oxide and Silver Sulfadiazine against Gram-Negative, Gram-Positive, and Antibiotic-Resistant Pathogens |
| Q40334600 | The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an early stage by interfering with the transactivating activity of viral immediate-early 2 protein |
| Q68449202 | The Synergistic Effect of Cefotaxime and Desacetylcefotaxime against Clinical Isolates of Anaerobic Bacteria |
| Q35540899 | The biosynthesis and interconversion of purines and their derivatives. |
| Q42932779 | The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro |
| Q39865219 | The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions |
| Q33840734 | The mononuclear molybdenum enzymes |
| Q39852169 | The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study |
| Q33664842 | Therapeutic trial of trimethoprim as a potentiator of sulphonamides in gonorrhoea |
| Q41312545 | Therapeutic trials with cytostatics (author's transl) |
| Q33743500 | Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine |
| Q28364106 | Toxicity of co-trimoxazole in nutritional haematinic deficiency |
| Q54557536 | Trimethoprim enhances the antibacterial activity of nalidixic and oxolinic acids and delays the emergence of resistance. |
| Q24676377 | Trimethoprim, a sulphonamide potentiator |
| Q39471967 | Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. |
| Q33692063 | Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics |
| Q53877959 | [Penetration of sulfamethoxazole and trimethoprim into the anterior chamber in humans (author's transl)]. |
| Q67251679 | [Potentiation by EDTA and levallorphan of the effect of sulfamethoxazole-trimethoprim on Escherichia coli] |
| Q98289837 | cGAS-STING pathway in oncogenesis and cancer therapeutics |
Search more.